Diphtheria:

NICD recommendations for diagnosis, management and public health response
Version 1.0 (7th May 2015):

J Thomas (NICD, DPHSR)
G Ntshoe (NICD, DPHSR)

Version 2.1 (22nd March 2016):

Guidelines writing committee (in alphabetical order):

C Cohen, (NICD, CRDM)
L de Gouveia (NICD, CRDM)
M du Plessis, (NICD, CRDM)
K McCarthy (NICD, DPHSR)
K Mlisana (UKZN)
P Moodley (KZN DoH)
G Ntshoe (NICD, DPHSR)
N Wolter, (NICD, CRDM)
A von Gottberg, (NICD, CRDM)

Guideline review:

Version 2.2: To be submitted to NHLS Microbiology expert working group

Summary of changes:

<table>
<thead>
<tr>
<th>Date reviewed</th>
<th>Reviewed by</th>
<th>Summary of changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version 2.0</td>
<td>Guideline writing committee</td>
<td>Case definitions changed</td>
</tr>
<tr>
<td>September 2015</td>
<td></td>
<td>Laboratory diagnostics section updated</td>
</tr>
<tr>
<td></td>
<td></td>
<td>References and ‘quick reference guide’ added</td>
</tr>
</tbody>
</table>

Disclaimer:

The information contained in this document, be it guidelines, recommendations, diagnostic algorithms or treatment regimens, are offered in this document in the public interest. To the best of the knowledge of the guideline writing team, the information contained in these guidelines is correct. Implementation of any aspect of these guidelines remains the responsibility of the implementing agency in so far as public health liability resides, or the responsibility of the individual clinician in the case of diagnosis or treatment.
Quick Reference Guide - Diphtheria

**Diphtheria case definitions:**

A diphtheria ‘case under investigation’:

A person who presents with an upper-respiratory tract illness characterised by sore throat, low-grade fever **AND** an adherent membrane of the nose, pharynx, tonsils, or larynx.

A confirmed case of diphtheria:

A person presenting with an upper respiratory tract symptoms with or without an adherent membrane **AND** culture or detection by PCR of *C. diphtheriae* or *C. ulcerans* or *C. pseudotuberculosis* from a clinical specimen which is confirmed to be toxin producing by ELEK testing or tox gene positive by PCR.

For case definitions of probable & possible cases, and asymptomatic carriers, see page 12

**Laboratory identification of *C. diphtheriae***

1. Take a throat swab from the affected area
2. Plate the swab for single colonies on blood agar (incubate at 37°C in CO₂ for 24 hours) and on selective tellurite-containing media (incubated at 37°C in O₂ for 48 hours)
3. *C. diphtheriae* form black colonies on tellurite-agar, and look similar to staphylococci on blood agar. They are catalase-positive Gram-positive bacilli
4. Confirm identification using API Coryne, or VITEK or other microbiological ID system
5. Submit the isolate to NICD for PCR and ELEK testing for detection of tox gene and determination of toxin production, respectively.

**Notification of cases and additional support:**

Laboratory support: National Institute for Communicable Diseases, Centre for Respiratory Diseases and Meningitis: Linda de Gouveia 011-555-0327 lindad@nicd.ac.za or Nicole Wolter 011-555-0352 nicolew@nicd.ac.za, or after-hours, the NICD doctor-on-call 082 883 9920:

Public health support and notification of cases: Notify the Provincial Communicable Diseases Control Officer, or the NICD Outbreak Response unit (011-555-0542) or outbreak@nicd.ac.za.

**Management of contacts of persons with diphtheria:**

1. Identify ‘close’ and ‘at-risk’ contacts
2. Take a nasopharyngeal swab from all contacts if possible. An oropharyngeal swab is acceptable but not ideal.
3. Administer chemoprophylaxis
4. Vaccinate contacts appropriately (depending on vaccination status. All contacts require at least a booster).
5. Monitor contacts for at least 10 days for signs and symptoms.

**For laboratory staff:**

Routinely to screen all throat and nose swabs for *C. diphtheriae* in the light of the KZN outbreak in 2015.

Please send any suspected/confirmed isolates of *Corynebacterium* spp. to CRDM/NICD for identification/confirmation and further characterisation. Please INCLUDE the original specimen/s (swab or tissue) for PCR testing.

Treatment of a case of diphtheria:

1. **Isolate:** prevent transmission of *C. diphtheriae* by practicing contact and droplet precautions
2. **Provide supportive care:** Provide oxygen, monitor with ECG and intubate or perform a tracheostomy if necessary
3. **Provide diphtheria antitoxin** according to severity of illness and mass of patient
4. **Treat with antibiotics.**
# Table of Contents

1. **Introduction** .................................................................................................................. 5
2. **Microbiology** .................................................................................................................. 5
3. **Epidemiology** ...................................................................................................................... 6
   3.1. Global epidemiology of diphtheria .................................................................................. 6
   3.2. Epidemiology of diphtheria in South Africa ..................................................................... 6
4. **Pathogenesis, pathology and transmission** ....................................................................... 6
5. **Clinical presentation and risk factors for diphtheria** ........................................................ 7
   5.1. Respiratory diphtheria ..................................................................................................... 7
   5.1.1. Local symptoms and clinical findings ......................................................................... 7
   5.1.2. Systemic manifestations ............................................................................................. 8
   5.2. Cutaneous diphtheria ...................................................................................................... 9
7. **Case definition and classification** ..................................................................................... 10
6. **Laboratory diagnosis of diphtheria** .................................................................................... 11
   6.1. Specimen collection for culture and/or PCR from suspected cases of respiratory or cutaneous diphtheria ........................................................................................................ 11
   6.1.1. Procedure for the collection of throat swabs from persons with suspected diphtheria ................................................................................................................................. 11
   6.1.2. Procedure for the collection of nasopharyngeal swabs from contacts of persons with suspected or proven diphtheria .................................................................................. 11
   6.1.3. Procedure for the collection of pus swabs or tissue .................................................... 12
   6.2. Processing of specimens for the detection of *C. diphtheriae* ......................................... 12
   6.2.1. Staining and microscopic examination of specimens .................................................. 12
   6.2.2. Procedure for the isolation of *C. diphtheriae* from culture of clinical specimens ...... 12
   6.2.3. Procedure for the confirmation of suspected *C. diphtheriae* isolates through biochemical testing .......................................................................................................................... 13
   6.2.4. Procedure for the confirmation of toxin production in confirmed *C. diphtheriae* isolates 13
6.3 Transport of specimens to NICD .......................................................................................... 13
8. **Management and treatment of diphtheria** ......................................................................... 14
   8.1. Infection prevention and control considerations ............................................................ 14
   8.2. Supportive care ............................................................................................................... 14
   8.3. Diphtheria antitoxin treatment (DAT) .......................................................................... 15
   8.4. Antibiotic treatment ...................................................................................................... 15
9. **Control and prevention of diphtheria** ............................................................................... 16
10. **Recommended public health response to a case of diphtheria in South Africa** .................. 17
11. **References** ..................................................................................................................... 19
1. Introduction

Diphtheria is caused by Corynebacterium diphtheriae, and presents most commonly as a membranous pharyngitis, although other presentations such as cutaneous disease also occur. The organism produces a toxin that causes necrosis of the tissues, leading to respiratory obstruction, and also myocarditis, leading to heart failure and death. The mortality of diphtheria was as high as 50%1 but fell to about 15% after antitoxin use became widespread. However, after introduction of the vaccine in the United Kingdom and subsequently worldwide in the 1940-50s2, diphtheria was practically eradicated and clinical diphtheria become an uncommon disease globally, and in South Africa. However there is presently global concern that diphtheria is re-emerging. A number of outbreaks of diphtheria have been reported from Eastern Europe3, Southeast Asia, South America4, North Africa5 and the Indian subcontinent. Persons (most especially children) who are not vaccinated or are partially vaccinated are most at risk of diphtheria1. Adults are also at risk as immunity due to vaccination wanes over time1. The first version of these guidelines were written in response to a diphtheria outbreak in Kwa-Zulu Natal Province of South Africa from March to June, 2015.

2. Microbiology

Diphtheria is caused by infection with toxin-producing (toxigenic) strains of Corynebacterium diphtheriae, C. ulcerans or rarely C. pseudotuberculosis. C. diphtheriae is a nonsporulating, unencapsulated, nonmotile, pleomorphic, gram-positive bacillus. When viewed under light microscopy, ‘metachromatic granules’ can be seen (best seen on methylene blue staining), along with a characteristic “Chinese character” palisading morphology6. Formerly, isolates of C. diphtheriae were typed using biochemical reactions into four biovars – gravis, intermedius, mitis and belfanti, but these methods of strain differentiation have been superseded by molecular methods (ribotyping) and subsequently by whole genome sequencing.

Corynebacterium diphtheriae and rare strains of C. ulcerans produce a toxin encoded on a lysogenic bacteriophage carrying the tox gene that is responsible for the pathogenesis and clinical presentation of diphtheria. Following infection, the phage’s circular DNA integrates into the host bacteria’s genetic material. Production of the toxin follows. Lysis of the cell releases the toxin and a new bacteriophage. The toxin is a 62,000-dalton polypeptide, that has a B sub-unit (which binds and facilitates cell entry), and an A subunit, that inhibits protein synthesis in a variety of tissues including the heart (where it causes myocarditis) and nerves (where it causes demyelination). Toxin production is regulated by the diphtheria toxin repressor protein (DtxR) which is also present in many non-toxigenic isolates. Therefore non-toxigenic isolates serve as a potential reservoir for the re-emergence of toxigenic isolates if they are possess functional dtxR genes and become infected with a tox gene-carrying phage.
3. Epidemiology

3.1. Global epidemiology of diphtheria

Following widespread immunisation programmes, diphtheria has declined or been eliminated from many developed countries\(^7\). The disease remains endemic in some developing countries, including the Indian subcontinent, Haiti, Brazil, Nigeria, Indonesia, Philippines, and some Eastern Mediterranean countries. The former Soviet Union states experienced a large epidemic of diphtheria during the 1990s, when >157,000 cases and 5,000 deaths were reported\(^3,8\). Diphtheria usually occurs among susceptible (i.e. non-immune) individuals, and usually reflects inadequate vaccination coverage. Cutaneous diphtheria has been reported predominantly in endemic tropical countries\(^2\). Recently, there has been increasing case reports of travellers acquiring cutaneous diphtheria associated with both non-toxigenic and toxigenic *C. diphtheriae*. The travel destinations associated with exposure to *C. diphtheriae* include the Indian subcontinent, the Middle East, Africa (including Nigeria, Kenya, Angola, and more recently Mozambique), South Pacific (Indonesia, Philippines, Papua New Guinea), South East Asia (Thailand, Cambodia, Vietnam), South America (Brazil, Dominican Republic), Haiti, and certain eastern European countries (in particular Latvia and Russia).

3.2. Epidemiology of diphtheria in South Africa

Since the implementation of diphtheria immunisation in South Africa in the 1950s only sporadic cases of disease (mostly involving children aged <15 years) have been identified and reported. Between January 2008 and March 2015, three laboratory-confirmed cases of respiratory diphtheria were reported: two from Western Cape Province (March 2008 and January 2010), and one from Eastern Cape Province (March 2009). The 2015 outbreak of diphtheria in Kwa-Zulu Natal involved 15 diphtheria cases (11 confirmed, 1 probable, 3 possible) of whom four died, with the first case presenting on 15\(^{th}\) March 2015, and the last case reported on 13\(^{th}\) June 2015. Six asymptomatic carriers of laboratory-confirmed toxigenic *C. diphtheriae* were identified. Cases ranged in age from 4 to 41 years (median 10 years). Children aged <15 years accounted for 73% (11/15) of the cases, with 40% (6/15) occurring in those aged 5 to 9 years. Males accounted for 60% (9/15) of cases. Where vaccination history was verified (n=6), four case-patients were not up to date with their diphtheria immunisations according to age. Outbreak response included the provision of antibiotics to close contacts, catch-up vaccination campaigns and health promotion activities. Diphtheria antitoxin was obtained through a generous donation by the Japanese government, and was administered to six case-patients.

4. Pathogenesis, pathology and transmission

Humans are the only known natural host for *C. diphtheriae*. By contrast, *C. ulcerans* and *C. pseudotuberculosis* are zoonotic diseases in humans (acquired from domesticated or wild animals), although human-to-human transmission of these pathogens has been suggested in some cases. *C. diphtheriae*, *C. ulcerans* and *C. pseudotuberculosis* are spread via large respiratory droplets or direct contact with infected skin lesions or respiratory secretions, or
rarely by fomites. After colonisation of the pharynx, *C. diphtheriae* remains in the superficial layers of the respiratory mucosa or skin lesions. The incubation period for respiratory diphtheria is usually 2-5 days, but may range from 1-10 days. Diphtheria toxin causes local tissue necrosis which leads to inflammation, ulceration and oedema of affected tissues, and results in the formation of a classic pseudomembrane. Additionally, diphtheria toxin can be absorbed into the bloodstream, causing a variety of systemic effects including myocarditis and demyelinating peripheral neuritis. Rarely, *C. diphtheriae* may disseminate from the respiratory tract or skin to cause distant systemic infections, including bacteraemia, endocarditis and septic arthritis.

Persons with respiratory diphtheria are contagious during disease, but may also be contagious during the incubation period (when they are asymptomatic), and sometimes also during convalescence (when carriage may last many weeks). Healthy persons may also be asymptomatic nasopharyngeal carriers of toxigenic corynebacteria. Carriage can be eradicated by appropriate antibiotic treatment. Cutaneous diphtheria is likely more transmissible than respiratory diphtheria, and can cause secondary respiratory and cutaneous infections and may even be a source of outbreaks. In endemic countries, cutaneous diphtheria lesions probably act as silent reservoirs of disease.

5. Clinical presentation and risk factors for diphtheria

5.1. Respiratory diphtheria

The classic presentation of diphtheria is associated with extensive pseudomembranous pharyngitis, massive swelling of the tonsils, uvula, cervical lymph nodes, submandibular region, and anterior neck (‘bull neck’). Following an average incubation period of 2-5 days (range 1-10 days), the onset of disease is usually gradual and initial symptoms include low-grade fever, malaise, cervical lymphadenopathy and sore throat. Respiratory diphtheria may occur in persons with incomplete primary vaccination series, or more rarely, in persons who have been vaccinated. However, disease in persons with prior vaccination is mild, and systemic symptoms do not occur.

5.1.1. Local symptoms and clinical findings

Pharyngeal infection commences with erythema, and progresses to isolated spots of grey and white exudate. Finally the exudate coalesces into a pseudomembrane. The pseudomembrane is usually found on the tonsils, and may extend to involve the tonsillar pillars, uvula, soft palate, oropharynx, nasopharynx or even tracheobronchial mucosa. The membrane is initially glossy and white, but evolves to a dirty grey-white colour; necrotic green or black patches on the membrane may also be seen. The membrane is fibrinous and firmly adherent, and typically bleeds when scraped or dislodged. The extent of the pseudomembrane generally correlates with the severity of disease. Localised tonsillar disease is usually mild, but involvement of posterior pharynx, soft palate and periglottal areas is often associated with more severe generalised symptoms (malaise and weakness), more severe local symptoms (including extremely painful throat, difficulty swallowing, and drooling), and cervical swelling due to cervical
lymphadenopathy and oedema of the anterior cervical tissues. Marked cervical lymphadenopathy and swelling result in the classical ‘bull-neck’ appearance of severe respiratory diphtheria, and results in respiratory stridor. Hoarseness and barking cough usually indicate laryngeal involvement, and tracheobronchial involvement is usually associated with dyspnoea and respiratory compromise.

5.1.2. Systemic manifestations
Systemic manifestations occur following absorption and dissemination of the diphtheria toxin through the bloodstream to other organs, most importantly the heart, nervous system and kidneys. The risk of developing cardiac and/or neurological toxicity is proportional to the severity of local infection; in one large outbreak 30% of patients hospitalised with severe forms of respiratory diphtheria developed systemic manifestations, with cardiac complications being the most common.

Myocarditis is the most common cardiac complication (and the most common systemic complication overall), and subtle evidence of myocarditis (as evidenced by ECG changes including ST-T wave changes, QTc prolongation, or first-degree heart block) can be detected in as many as two-thirds of patients. Up to 25% of patients develop clinical cardiac dysfunction, with the severity proportional to that of the local disease. Cardiac toxicity can be acute (manifesting during illness), or delayed (manifesting 7-14 days after the onset of respiratory symptoms during recovery). Acute cardiac toxicity presents as cardiac failure and circulatory collapse, whilst delayed toxicity presents as progressive dyspnoea, weakness, diminished heart sounds, cardiac dilatation and gallop rhythm.

Subtle ECG changes (particularly ST-T wave changes and first degree heart block) can progress to severe forms of heart block, AV dissociation and other arrhythmias which carry a poor prognosis. Because patients without clinical evidence of myocarditis may have significant ECG changes, it is important to monitor ECG patterns regularly in all patients with diphtheria. Serum AST levels may also be useful in monitoring myocarditis.

Neurological complications occur in about 5% of cases overall but up to 75% of patients with severe diphtheria develop some manifestation of neurological involvement. Local neuropathies (i.e. paralysis of the soft palate and posterior pharynx) are most common in the first few days of disease, and manifest as regurgitation of swallowed fluids through the nose. Cranial neuropathies (most commonly oculomotor and ciliary, but also facial or laryngeal cranial nerves) may also occur later in the course of disease. Demyelinating peripheral neuritis is a delayed complication, usually developing weeks to months after acute disease and ranges from mild weakness with diminished tendon reflexes, to total paralysis. Predominantly a motor deficit, it usually begins as proximal weakness in the upper and lower limbs, extending distally. Neurologic toxicity usually resolves completely, but may be slow with prolonged convalescence.

Renal complications may develop as a direct effect of the toxin on the kidney and may result in renal failure.
5.2. **Cutaneous diphtheria**

Unlike respiratory diphtheria where the incubation period is known, the incubation period for cutaneous diphtheria is not well-defined and may be much longer than the range for respiratory disease. Persons with cutaneous diphtheria may subsequently develop respiratory diphtheria and serious complications. Cutaneous diphtheria can occur in persons who have been fully vaccinated, as is the case with respiratory diphtheria. Disease in such persons is usually milder, and they rarely develop systemic toxic manifestations. The types and appearance of cutaneous diphtheria are extremely variable.  

*C. diphtheriae* can colonise existing skin lesions such as those resulting from surgery or trauma, or from underlying skin conditions (pyoderma, eczema, impetigo, dermatitis) and insect bites.  

Chronic non-healing ulcers are the typical manifestation of cutaneous diphtheria, usually with a time course of weeks to months. An ulcerative lesion (historically termed ‘ecthyma diphtheriticum’) is often the presenting lesion; it begins as a vesicle or pustule filled with straw-coloured fluid which breaks down quickly. The lesion then progresses to form a punched-out ulcer (or multiple ulcers) of variable size, often with elevated margins. Lesions are initially painful and may be covered with an adherent eschar (essentially a dark pseudomembrane) during the first 2 weeks. The lesion then becomes painless and the pseudomembrane falls away leaving a haemorrhagic base, sometimes associated with a serous/serosanguinous exudate. The surrounding tissue is oedematous and may be pink, purple or dark in colour; there may be blisters and even bullae in some cases. In mild forms of the disease, a scaling rash may be the only manifestation. Common sites for lesions include lower legs, feet and hands. Bacterial co-infection of cutaneous diphtheria lesions is common, most notably with *Staphylococcus aureus* and *Streptococcus pyogenes*. This may mask or delay the diagnosis of cutaneous diphtheria.

5.3. **Other presentations of diphtheria**

Localised infection with *C. diphtheriae* is occasionally seen in unusual sites, including the ear, conjunctivae or vagina. Invasive disease due to toxigenic *C. diphtheriae* does occur, but is uncommon; bacteraemia, endocarditis and septic arthritis have been described.

5.4. **Non-toxigenic *C. diphtheriae***

Non-toxigenic *C. diphtheriae* typically causes chronic skin ulceration; less common manifestations include upper respiratory tract infections, or rarely, invasive diseases (including endocarditis, mycotic aneurysms, osteomyelitis and septic arthritis). Classically, persons with underlying medical conditions (including alcoholism and IV drug users) appear to be at higher risk of developing sporadic invasive disease from non-toxigenic *C. diphtheriae*. However, in the last two decades clusters and outbreaks of invasive disease caused by unique epidemic strains of non-toxigenic *C. diphtheriae* disease have been described in marginalised social groups (homeless persons in the US, urban poor in Canada, Australian aboriginal populations) with high morbidity and mortality.
### 6. Case definition and classification

**Table 1. Case definitions including clinical, epidemiological and laboratory criteria for respiratory diphtheria**

<table>
<thead>
<tr>
<th>Case definition</th>
<th>Clinical criteria</th>
<th>Epidemiologic criteria</th>
<th>Laboratory criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspected case</td>
<td>A person who presents with an upper-respiratory tract illness characterised by sore throat, low-grade fever AND an adherent membrane of the nose, pharynx, tonsils, or larynx</td>
<td>None required</td>
<td>None required</td>
</tr>
<tr>
<td>Confirmed case</td>
<td>A person presenting with upper respiratory tract symptoms with or without an adherent membrane ( ^a )</td>
<td>AND None required</td>
<td>AND Culture or detection by PCR of <em>C. diphtheriae</em> or <em>C. ulcerans</em> or <em>C. pseudotuberculosis</em> from a clinical specimen which is confirmed to be tox gene positive by PCR or toxin-producing by ELEK testing</td>
</tr>
<tr>
<td>Probable case</td>
<td>A person who meets the suspected case definition or who has respiratory tract symptoms but no membrane ( ^b )</td>
<td>AND Has an epidemiologic link to a laboratory-confirmed case or asymptomatic carrier</td>
<td>AND Laboratory testing for diphtheria is inconclusive or has not been performed OR Clinical specimens have yielded one of <em>C. diphtheriae</em>/<em>C. ulcerans</em>/<em>C. pseudotuberculosis</em> but toxigenicity status has not been confirmed</td>
</tr>
<tr>
<td>Possible case ( ^c )</td>
<td>A person who meets the suspected case definition</td>
<td>AND No epidemiologic link to a laboratory-confirmed case</td>
<td>AND Laboratory testing for diphtheria is inadequate or has not been performed</td>
</tr>
<tr>
<td>Asymptomatic carrier</td>
<td>No symptoms</td>
<td>AND With or without an epidemiologic link to a laboratory-confirmed case</td>
<td>AND Culture or detection by PCR of <em>C. diphtheriae</em> or <em>C. ulcerans</em> or <em>C. pseudotuberculosis</em> from a clinical specimen which is confirmed to be tox gene positive by PCR or toxin-producing by ELEK testing</td>
</tr>
<tr>
<td>Unclassified</td>
<td>A person presenting with an upper respiratory tract infection or other signs or symptoms compatible with diphtheria</td>
<td>AND None required</td>
<td>AND <em>C. diphtheriae</em>/<em>C. ulcerans</em>/<em>C. pseudotuberculosis</em> is isolated but is confirmed to be a non-toxigenic strain</td>
</tr>
<tr>
<td>Discarded cases</td>
<td>A person who presents with an upper-respiratory tract illness characterized by sore throat, low-grade fever AND an adherent membrane of the nose, pharynx, tonsils, or larynx</td>
<td>AND No epidemiologic links to a laboratory-confirmed or probable case</td>
<td>AND Adequate laboratory testing has not identified <em>C. diphtheriae</em>/<em>C. ulcerans</em>/ <em>C. pseudotuberculosis</em> OR Laboratory testing yielded a non-diphtheroid organism compatible with the clinical presentation (e.g. <em>Streptococcus pyogenes</em>)</td>
</tr>
</tbody>
</table>

\( ^a \) Confirmed diphtheria is possible even when persons do not have a membrane

\( ^b \) It would be unwise to exclude persons with pharyngeal symptoms and no membrane, who have an epidemiological link to a confirmed case, when laboratory testing is not done, or is inconclusive.

\( ^c \) When persons with clinical symptoms compatible with diphtheria (including a pharyngeal membrane) have no epidemiological link with a confirmed case, and laboratory testing is not possible, or inadequate, extensive epidemiological investigations should be done, including laboratory investigations of contacts. If asymptomatic carriers are found, the case will be reassigned to the probable category. Given the findings of the outbreak in KZN and the recognition that vaccination coverage amongst 6 and 12 year old children is sub-optimal, this category exists in order to broaden case detection.

---

*Guidelines_Diphtheria_20160322_v2.3* Page 10 of 19
7. Laboratory diagnosis of diphtheria

7.1. Specimen collection for culture and/or PCR from suspected cases of respiratory or cutaneous diphtheria

Swabs should be taken from the nose, throat, underneath the pseudomembrane (if present) or wound. Pieces of pseudomembrane may also be collected. Dacron, Rayon or nylon-flocked swabs should be used and placed in Amies or Stuart’s transport media. Pieces of pseudomembrane should be placed in sterile saline (not formalin). Specimens must be transported to the laboratory, with ice packs, as soon as possible. Please use the specimen submission form on the NICD website.

Persons may find the collection of pharyngeal and particularly nasopharyngeal swabs exceptionally uncomfortable. The procedures usually induce coughing, spluttering, sneezing and watering eyes. It is important that persons collecting the specimen are appropriately protected. Droplet precautions are necessary, including a surgical mask. Eye protection may be advisable. Persons collecting the swabs should ensure that they are adequately protected through vaccination, and that booster vaccines against diphtheria are up to date.

Figure 1: Amies transport media (with charcoal) used for the transport of throat and nasal swabs

7.1.1. Procedure for the collection of throat swabs from persons with suspected diphtheria

- The pharynx should be clearly visible and well illuminated.
- Depress the tongue with a tongue-depressor and swab the throat without touching the tongue or inside the cheeks.
- Rub vigorously over any membrane, white spots, or inflamed areas; slight pressure with rotating movement must be applied to the swab.
- If any membrane is present, lift the edge and swab beneath it to reach the deeply located organisms.
- Place the swab in Amies transport medium and dispatch immediately to the laboratory for culture.

7.1.2. Procedure for the collection of nasopharyngeal swabs from contacts of persons with suspected or proven diphtheria

- Through one nostril, insert the swab into the nose beyond the anterior nares.
- Gently introduce the swab along the floor of the nasal cavity, under the middle turbinate, until the pharyngeal wall is reached.
- Force must not be used to overcome any obstruction.
- Place the swab in Amies transport medium and dispatch immediately to the laboratory for culture.

7.1.3. **Procedure for the collection of pus swabs or tissue**

**Skin lesions**
- Lesions should be cleaned with sterile normal saline and crusted material removed
- Press the swab firmly into the lesion.
- Transport the swab immediately to the laboratory for culture.

**Tissue specimens**
- If sections of membrane are removed, they should be placed in a universal specimen container in sterile saline and transported immediately to the laboratory for culture. Specimens for culture must NOT be placed in formalin.
- Additional tissue specimens may be collected for submission to the histopathology laboratory if desired.

7.2. **Processing of specimens for the detection of C. diphtheriae**

7.2.1. **Staining and microscopic examination of specimens**

The ‘chinese lettering’ that is typical of coryneform bacteria and the metachromatic granules that are specific to *C. diphtheriae* are not sufficiently sensitive nor specific enough to be useful in the diagnosis of diphtheria. Rather, diagnosis relies on the detection of *C. diphtheriae* through culture or PCR detection of the *tox* gene.

7.2.2. **Procedure for the isolation of C. diphtheriae from culture of clinical specimens**

- Roll the swab, or place the tissue on a segment of a blood agar plate and a solid agar plate of selective tellurite-containing media (e.g., Hoyle’s agar)
- Incubate the blood agar and selective media at 37°C in O₂ for 48 hours.
- Examine plates at 24 and 48 hours for colonies typical of *C. diphtheriae*. On selective media, colonies appear greyish black with a garlic-like odour (Figure 2A and B). Other Corynebacterium spp. and some staphylococci tolerate tellurite and thus may also grow on selective media and appear greyish black.
- Perform a Gram’s stain of typical colonies. Coryneform bacteria will appear as pleomorphic Gram-positive rods that occur in angular arrangements, (may appear coccobacillary in older cultures).
- Subculture suspicious colonies onto blood agar in order to carry out identification procedures.
Figure 2A: Typical colonial appearance after 18 hours incubation on Hoyle’s medium (~1mm in diameter, black matt colonies, bottom half of agar plate)

Figure 2B: Typical colonial appearance after 18 hours incubation on blood agar

7.2.3. Procedure for the confirmation of suspected C. diphtheriae isolates through biochemical testing

Traditional biochemical testing of C. diphtheriae will demonstrate a positive catalase reaction, and acid production from glucose and maltose, and not from lactose and sucrose. However, identification is most often through the use of commercial identification kits (e.g., API) or an automated system or Matrix-Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) technology.

7.2.4. Procedure for the confirmation of toxin production in confirmed C. diphtheriae isolates

Traditionally an Elek test is carried out to confirm toxin production of Corynebacterium species. Elek testing is available at the Centre for Respiratory Diseases and Meningitis (CRDM), and at Greenpoint NHLS Laboratory. Swabs or tissue can be tested by PCR for the presence of the A and B subunits of the diphtheria toxin gene (tox). This PCR assay is available at at the CRDM/NICD. The presence of the tox gene does not necessarily indicate that toxin is being produced, and this PCR assay does not distinguish between C. diphtheriae and C. ulcerans. Therefore the Elek test must be performed on all isolates suspected of causing clinical diphtheria. Isolates of C. diphtheriae (or Corynebacterium species) should be submitted for confirmation and toxigenicity testing by the Elek test. Isolates should be submitted as pure cultures heavily inoculated onto Dorset transport medium or other common agar slants or plates and submitted to NICD without delay at ambient temperature (not on ice). Submission should not be delayed for incubation of the Dorset or other medium. The organism will grow minimally as it travels at ambient temperature, and further incubation can be done at the NICD if necessary.

Figure 3: Submit suspected C. diphtheriae isolates to NICD on Dorset transport media, or send the blood or Hoyle’s agar plate (sealed in e.g. Parafilm M)

7.3. Transport of specimens to NICD

Specimens should be transported as soon as possible to: Centre for Respiratory Diseases and Meningitis (CRDM) bacteriology laboratory, National Institute for Communicable Diseases (NICD), 1 Modderfontein Road, Sandringham, Johannesburg, 2131. Please use specimen submission form attached at the end of these guidelines.
Additional information:
If you require additional information, please contact Centre for Respiratory Diseases and Meningitis (CRDM): Linda de Gouveia 011-555-0327 lindad@nicd.ac.za or Nicole Wolter 011-555-0352 nicolew@nicd.ac.za, or after-hours, the NICD doctor-on-call 082 883 9920.

The NICD offers assistance 24 hours a day, seven days a week, and may be contacted during office hours and after hours at the above numbers. It is important to contact CRDM/NICD before isolates arrive to ensure that they receive appropriate priority, especially on Fridays and during the weekends.

Diphtheria is a notifiable medical condition in South Africa. All suspected/probable/confirmed cases should be reported to infection prevention and control practitioners at healthcare facilities where applicable, as well as District and Provincial communicable disease control coordinators urgently (as per routine notifiable medical condition notification procedures).

8. Management and treatment of diphtheria
The mainstay of treatment of a suspected diphtheria case is prompt administration of diphtheria antitoxin (DAT); this should be given without waiting for laboratory confirmation of a presumptive diagnosis of diphtheria. DAT only neutralises toxin before its entry into cells so it is critical that DAT be administered as soon as possible after presentation. The recommended dosage and route of administration depend on the extent and duration of disease. Appropriate antibiotics should also be given, in order to eradicate carriage of the organism, limit transmission, and stop further production of diphtheria toxin.

8.1. Infection prevention and control considerations
Isolate all patients with suspected diphtheria until the diagnosis is confirmed or excluded. Isolate hospitalised patients with standard, contact (use of gloves and plastic aprons etc.) and droplet precautions (wearing a surgical face mask) until two cultures from the throat and nose (and skin lesions in cutaneous diphtheria) taken at least 24 hours apart after completion of antibiotic therapy are negative for toxigenic C. diphtheriae, C. ulcerans or C. pseudotuberculosis. In the absence of such follow-up cultures, patients should be isolated until they have completed 14 days of antibiotic therapy. Where patients are not hospitalised, restrict contact with others until completion of antibiotic therapy.

8.2. Supportive care
Refer all probable or confirmed diphtheria cases for specialist assessment by a paediatrician or an Ear, Nose and Throat surgeon. Patients with respiratory diphtheria require careful monitoring (ideally in a high or intensive care setting) for potentially life-threatening complications from local disease (e.g. airway obstruction or respiratory compromise due to tracheobronchial disease) or systemic manifestations (especially cardiac complications). Because patients without clinical evidence of myocarditis may have significant ECG changes, it is important to monitor ECG patterns regularly in all patients with diphtheria. Serum AST levels may also be used to monitor myocarditis.
8.3. **Diphtheria antitoxin treatment (DAT)**

DAT neutralises circulating unbound diphtheria toxin and prevents progression of disease. Since the antitoxin does not neutralize toxin that is already bound to tissues, delaying its administration is associated with an increased mortality. DAT should only be administered in a hospital setting. DAT should be given to all probable classic respiratory diphtheria cases without waiting for laboratory confirmation; a decision to administer DAT is based on clinical diagnosis, and should not await laboratory confirmation.

DAT is generally not indicated in cases of cutaneous diphtheria without systemic manifestations. However, in cases where the ulcer is very large (>2cm²) and membranous, the risk of systemic absorption of toxin and subsequent systemic complications is increased and DAT may be considered. The dosing of DAT is product-specific and is detailed in the package insert.

8.4. **Antibiotic treatment**

Antibiotic treatment is not a substitute for DAT treatment. Although antibiotics have not been demonstrated to affect healing of local infection, they are given to eradicate the organism from the nasopharynx and prevent further transmission to others. All diagnostic specimens should be collected before antibiotic treatment is started. However, should antibiotics already have been started, specimens should still be collected. Recommended antibiotics include macrolides (erythromycin, azithromycin or clarithromycin) or benzylpenicillin – refer to Table 2 for dosing guidance. Parenteral benzylpenicillin (or erythromycin if available) should be used until the patient is able to swallow, when oral treatment with either a macrolide or benzylpenicillin can be commenced. Antibiotic therapy must be given for a total of 14 days.

Elimination of the organism must be confirmed after antibiotic treatment is completed: two sets of nasopharyngeal and throat swabs must be collected for culture, taken at least 24 hours apart and more than 24 hours after completing antibiotics. If the toxigenic strain persists, an additional 10 days of antibiotic treatment is indicated.

Table 2: Antibiotic treatment for diphtheria

<table>
<thead>
<tr>
<th>1.</th>
<th>Parenteral treatment for patients unable to swallow</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Penicillin G*</td>
</tr>
<tr>
<td>Children</td>
<td>50 000 units/kg/dose IV 12 hourly</td>
</tr>
<tr>
<td>Adults</td>
<td>50 000 units/kg/dose (max 1.2 million units per dose) IV 12 hourly</td>
</tr>
</tbody>
</table>
2. Oral treatment for patients able to swallow

<table>
<thead>
<tr>
<th></th>
<th>Penicillin V*</th>
<th>Erythromycin</th>
<th>Macrolides*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Children</strong></td>
<td>15 mg/kg/dose</td>
<td>15-25 mg/kg/dose</td>
<td>10 mg/kg po daily</td>
</tr>
<tr>
<td></td>
<td>(maximum 500 mg per dose) po 6 hourly</td>
<td>(maximum 1g per dose) po 6 hourly</td>
<td></td>
</tr>
<tr>
<td><strong>Adults</strong></td>
<td>500 mg po 6 hourly</td>
<td>500 mg – 1g po 6 hourly</td>
<td>1. po daily</td>
</tr>
<tr>
<td></td>
<td>(maximum 4g/day)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Duration of antibiotic therapy is 14 days.

9. Control and prevention of diphtheria

Adherence to EPI vaccination schedule including primary vaccinations with diphtheria toxoid-containing vaccine, and booster vaccination at age 6 and 12 years is essential for the prevention of diphtheria. All persons who are diagnosed with confirmed or probable diphtheria should receive a booster dose of diphtheria-containing vaccine once they are clinically stable, as infection does not reliably induce protective antibody levels. The booster dose should be given as a diphtheria-toxoid containing vaccine appropriate to age and immunisation history (i.e. DTaP-IPV/Hib or DTaP-IPV/Hib/HBV or Td or Tdap-IPV). Offer an accelerated diphtheria vaccination series to children, adolescents or adults who are unimmunised or incompletely immunised (contact a vaccine-preventable disease expert to discuss this). Children who have completed their primary diphtheria vaccination series plus routine booster/s, and adolescents and adults who have been previously immunised can be offered a diphtheria-containing vaccine booster dose (Td or Tdap-IPV). Table 3 describes the currently available vaccines that may be used amongst specific persons.

Table 3. Currently available vaccines that are appropriate for the prevention of diphtheria*.

<table>
<thead>
<tr>
<th>Product name</th>
<th>Vaccine description</th>
<th>Appropriate indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pentaxim® (DTaP-IPV/Hib)</td>
<td>Diphtheria, tetanus, acellular pertussis, <em>Haemophilus influenza type b</em>, inactivated polio</td>
<td>Primary vaccination series, and booster at 18 months licenced for use in children aged 6 weeks to 7 years</td>
</tr>
<tr>
<td>Infranix® Hexa (DTaP-IPV/Hib/hep B)</td>
<td>Diphtheria, tetanus, acellular pertussis, <em>Haemophilus influenza type b</em>, inactivated polio and hepatitis B</td>
<td>Primary vaccination series, and booster at 18 months licenced for use in children aged 6 weeks to 7 years; can only be given at 6 weeks if Hep B given at birth, else commence schedule at 2 months.</td>
</tr>
<tr>
<td>Infanrix® (DTaP)</td>
<td>Diphtheria, tetanus, acellular pertussis</td>
<td>Primary vaccination series, and booster at 18 months, licenced for use in children aged 6 weeks to 7 years</td>
</tr>
<tr>
<td>Diftavax® (Td)</td>
<td>Diphtheria (reduced dose), tetanus</td>
<td>Routine booster immunisation. Licenced for use in persons 6 years and older</td>
</tr>
<tr>
<td>Adacel Quadra® Boostrix Tetra® (TdaP-IPV)</td>
<td>Tetanus, diphtheria (reduced dose), acellular pertussis, inactivated polio</td>
<td>Active immunisation or booster in persons aged 3 (Adacel Quadra®) or 4 years and older (Boostrix Tetra®)</td>
</tr>
</tbody>
</table>

10. Recommended public health response to a case of diphtheria in South Africa

Diphtheria is a notifiable medical condition in South Africa. All suspected/probable/confirmed cases should be reported to infection prevention and control practitioners at healthcare facilities where applicable, as well as district and provincial communicable disease control coordinators urgently (as per routine notifiable medical condition notification procedures). On notification of such case-patients the following public health actions should be initiated immediately:

**Step 1: Conduct a detailed case investigation**
- Obtain detailed demographic, clinical and risk factor information. A case-investigation form is available on the NICD web-site
- Compile a case line list and apply case definitions
- Compile a case contact line list

**Step 2: Identify contacts**
- Close contacts include:
  - Those having close contact with the patient in a household-type setting. This includes those living and/or sleeping in the same household; those such as scholars/students etc. who sleep in the same dormitory/flat or have shared kitchen facilities etc.; and kissing/sexual contacts of the patient
  - If the index case is a young child, persons who care for the child
  - Healthcare workers who have given mouth-to-mouth resuscitation to the patient or have dressed the wounds of a cutaneous case without appropriate infection control procedures
- At-risk contacts – for this group risk of disease will depend on the duration of contact and their immunization status. At-risk contacts need to be assessed on a case by case basis by health authorities to determine likely level of risk and need for prophylaxis. Examples of such contacts would include:
  - Friends, relatives, and caregivers who regularly visit the home
  - School/pre-school class contacts
  - Those who share the same room at work
  - Other healthcare workers who have had contact with the case

**Step 3: Conduct laboratory investigation of close contacts and eligible at-risk contacts**
- Collect nasopharyngeal swabs if possible, or (pharyngeal swabs if nasopharyngeal swabs are not possible, or will not be tolerated) for culture – this should ideally be done before chemoprophylaxis if possible.
- Should a contact test positive for toxigenic *C. diphtheriae*, the person will require full treatment and follow-up cultures as per symptomatic cases. Infection control measures should be implemented (isolation with standard, contact and droplet precautions) until two cultures (taken at least 24 hours apart) from both nose and throat >24 hours after completing antibiotic therapy are negative for *C. diphtheriae*. Disinfection of toys, pacifiers and other fomites that the patient used or touched should also be done.

**Step 4: Administer chemoprophylaxis to close contacts and at-risk contacts**
- Offer post-exposure chemoprophylaxis to all close contacts and eligible at-risk contacts to eliminate asymptomatic carriage and to treat incubating disease. Either benzylpenicillin or erythromycin may be used for chemoprophylaxis, as per Table 3.
Table 3. Chemoprophylaxis for close contacts and eligible at-risk contacts of diphtheria cases

<table>
<thead>
<tr>
<th>Age group</th>
<th>Benzylpenicillin</th>
<th>Erythromycin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;6 years</td>
<td>Single dose of 600 000 units I.M.</td>
<td>&lt;2 years: 125 mg every 6 hours po for seven days</td>
</tr>
<tr>
<td>&gt;6 years</td>
<td>Single dose of 1.2 million units I.M.</td>
<td>2-8 years: 250 mg every 6 hours po for seven days</td>
</tr>
<tr>
<td>Adults</td>
<td>Single dose of 1.2 million units</td>
<td>&gt;8 years: 500 mg every 6 hours po for seven days</td>
</tr>
</tbody>
</table>

Step 5: Monitor close and eligible at-risk contacts
Monitor close contacts and eligible at-risk contacts for signs/symptoms of diphtheria for at least 10 days after last contact with the index case. Educate them about the disease and advise them to seek medical care if they develop symptoms.

Step 6: Exclude close and eligible at-risk contacts in high-risk occupations
Those whose work involves handling food (especially those involved in milk production for C. ulcerans), those who work with unvaccinated children, or health and social care workers should be excluded from work until laboratory tests confirm that they are not carriers.

Step 7: Vaccinate close and eligible at-risk contacts
- Diphtheria vaccine is not indicated for routine post-exposure prophylaxis. However, it is an opportunity to check diphtheria vaccination status in contacts, and all unimmunised/incompletely immunised contacts ≤12 years of age should complete their primary vaccination and booster doses as per the EPI schedule
- Adolescents and adults may also be offered a booster dose of diphtheria-containing vaccine according to Table 3 above.

Step 8: Alert other healthcare facilities in the area
- Alert healthcare practitioners in the area and inform them to maintain a high index of suspicion for diphtheria amongst persons presenting with pharyngitis, or chronic, non-healing ulcers
- Provide fact sheets about the disease aimed at healthcare professionals

Step 9: Conduct health promotion activities and health education
- Identify at-risk populations, such as school children, health care workers for health promotion activities
- Produce and distribute information, education and communication materials that provide basic information about the disease and the vaccine and vaccine schedule
- Encourage good personal hygiene practices (hand hygiene and cough etiquette)

Step 10: Vaccination campaigns in response to outbreaks
In the event of an outbreak, selective vaccination campaigns targeting at-risk groups (including healthcare workers) may be considered.
11. References